#60 - Craig Boyce & Dr. Melanie Leitner: Can Venture Capital Cure ALS? episode artwork

EPISODE · Apr 23, 2025 · 1H 50M

#60 - Craig Boyce & Dr. Melanie Leitner: Can Venture Capital Cure ALS?

from Nothing Left Unsaid · host Tim Green & Troy Green

When private-equity veteran Craig Boyce left nearly two decades at Bain Capital and neuroscientist Dr. Melanie Leitner stepped out of the lab, both carried a deeply personal mission: speed up the end of ALS. Together they helm the ALS Investment Fund, a for-profit venture vehicle that backs early-stage therapeutics aimed at turning the disease from terminal to chronically managed by filling the “capital void” between basic research and big-pharma buy-in​. In this conversation with Tim and Troy, Craig recounts losing his father to ALS and how that tragedy redirected his deal-making skills toward impact investing​, while Melanie shares the “seventh-grade brain report” that launched her career and why today’s biomarker and platform-trial advances finally make true progress possible​. They break down: Why capital markets—not philanthropy alone—must fund $10-$50 M clinical trials ​ The business case that’s luring big pharma back to neuro (“the decade of neurodegeneration”) ​ How a cystic-fibrosis-style royalty model could recycle billions into ALS research ​ The audacious goal to “put ourselves out of business” by making effective therapies commonplace ​ If you’re curious how finance, science, and relentless human stories converge to accelerate cures, this episode delivers a front-row seat. SPONSORS: ElevenLabs: Thanks to ElevenLabs (https://elevenlabs.io) for supporting this episode and powering Tim’s voice. ALS Investment Fund: Thanks to ALS Investment Fund (https://www.alsinvestmentfund.com) for supporting this episode. SOCIAL: Website: https://tgnlu.com   Twitter: https://twitter.com/nlutimgreen   Facebook: https://www.facebook.com/NLUpod  Instagram: https://www.instagram.com/nlupod/  AUDIO ONLY: Spotify: https://open.spotify.com/show/5fhcANt7CSnYvgBlgxpVVa  Apple Podcasts: https://podcasts.apple.com/us/podcast/nothing-left-unsaid/id1734094890   PERSONAL:  Tackle ALS: https://www.tackleals.com   Tim Green Books: https://authortimgreen.com Learn more about your ad choices. Visit megaphone.fm/adchoices

When private-equity veteran Craig Boyce left nearly two decades at Bain Capital and neuroscientist Dr. Melanie Leitner stepped out of the lab, both carried a deeply personal mission: speed up the end of ALS. Together they helm the ALS Investment Fund, a for-profit venture vehicle that backs early-stage therapeutics aimed at turning the disease from terminal to chronically managed by filling the “capital void” between basic research and big-pharma buy-in​. In this conversation with Tim and Troy, Craig recounts losing his father to ALS and how that tragedy redirected his deal-making skills toward impact investing​, while Melanie shares the “seventh-grade brain report” that launched her career and why today’s biomarker and platform-trial advances finally make true progress possible​. They break down: Why capital markets—not philanthropy alone—must fund $10-$50 M clinical trials ​ The business case that’s luring big pharma back to neuro (“the decade of neurodegeneration”) ​ How a cystic-fibrosis-style royalty model could recycle billions into ALS research ​ The audacious goal to “put ourselves out of business” by making effective therapies commonplace ​ If you’re curious how finance, science, and relentless human stories converge to accelerate cures, this episode delivers a front-row seat. SPONSORS: ElevenLabs: Thanks to ElevenLabs (https://elevenlabs.io) for supporting this episode and powering Tim’s voice. ALS Investment Fund: Thanks to ALS Investment Fund (https://www.alsinvestmentfund.com) for supporting this episode. SOCIAL: Website: https://tgnlu.com   Twitter: https://twitter.com/nlutimgreen   Facebook: https://www.facebook.com/NLUpod  Instagram: https://www.instagram.com/nlupod/  AUDIO ONLY: Spotify: https://open.spotify.com/show/5fhcANt7CSnYvgBlgxpVVa  Apple Podcasts: https://podcasts.apple.com/us/podcast/nothing-left-unsaid/id1734094890   PERSONAL:  Tackle ALS: https://www.tackleals.com   Tim Green Books: https://authortimgreen.com Learn more about your ad choices. Visit megaphone.fm/adchoices

NOW PLAYING

#60 - Craig Boyce & Dr. Melanie Leitner: Can Venture Capital Cure ALS?

0:00 1:50:32

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Nothing Left Unsaid?

This episode is 1 hour and 50 minutes long.

When was this Nothing Left Unsaid episode published?

This episode was published on April 23, 2025.

What is this episode about?

When private-equity veteran Craig Boyce left nearly two decades at Bain Capital and neuroscientist Dr. Melanie Leitner stepped out of the lab, both carried a deeply personal mission: speed up the end of ALS. Together they helm the ALS Investment...

Can I download this Nothing Left Unsaid episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!